Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kura Oncology (KURA) EPS (Weighted Average and Diluted) (2023 - 2026)

Kura Oncology has reported EPS (Weighted Average and Diluted) over the past 4 years, most recently at -$0.83 for Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 25.76% to -$0.83 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$2.34 through Mar 2026, down 11.43% year-over-year, with the annual reading at -$3.18 for FY2025, 57.43% down from the prior year.
  • EPS (Weighted Average and Diluted) was -$0.83 for Q1 2026 at Kura Oncology, down from $2.25 in the prior quarter.
  • Over five years, EPS (Weighted Average and Diluted) peaked at $2.25 in Q4 2025 and troughed at -$0.85 in Q3 2025.
  • The 4-year median for EPS (Weighted Average and Diluted) is -$0.59 (2024), against an average of -$0.38.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 1123.24% in 2025 against a maximum downside of 34.23% in 2025.
  • A 4-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.55 in 2023, then skyrocketed by 60.0% to -$0.22 in 2024, then skyrocketed by 1123.24% to $2.25 in 2025, then tumbled by 136.87% to -$0.83 in 2026.
  • Per Business Quant, the three most recent readings for KURA's EPS (Weighted Average and Diluted) are -$0.83 (Q1 2026), $2.25 (Q4 2025), and -$0.85 (Q3 2025).